Damora Therapeutics
DMRA
10 hedge funds and large institutions have $661K invested in Damora Therapeutics in 2024 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 3 closing their positions.
0.47% more ownership
Funds ownership: 10.29% → 10.76% (+0.47%)
0% more funds holding
Funds holding: 10 → 10 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
58% less capital invested
Capital invested by funds: $1.56M → $661K (-$902K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Squarepoint
New York
|
+$83.1K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$48.2K |
| 3 |
JP Morgan Chase
New York
|
+$654 |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$7 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$41.5K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4.2K |
| 3 |
Morgan Stanley
New York
|
-$392 |
| 4 |
HI
Harbour Investments
Madison,
Wisconsin
|
-$97 |
| 5 |
DB
Danske Bank
Copenhagen K,
Denmark
|
-$85 |
DMRA Hedge Fund Activity: Q4 2024 in Review
10 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Damora Therapeutics (DMRA) for Q4 2024, worth a combined $661K — down 58% from $1.56M a quarter earlier.
Fund positioning in DMRA was balanced in Q4 2024: 3 funds opened new positions, 3 closed out, 2 added to existing stakes and 2 trimmed.
The largest buyer was Squarepoint, opening a new position worth an estimated $83.1K. The largest seller was Renaissance Technologies, cutting an estimated $41.5K.
- 10 institutional investors held Damora Therapeutics (DMRA) as of Q4 2024, unchanged from Q3 2024.
- Funds reported $661K of Damora Therapeutics stock for Q4 2024, down 58% quarter-over-quarter.
- 3 funds opened new Damora Therapeutics positions in Q4 2024 and 3 closed out, a net change of 0 holders.
- The largest Damora Therapeutics buyer in Q4 2024 was Squarepoint, an estimated $83.1K added.
- The largest Damora Therapeutics seller in Q4 2024 was Renaissance Technologies, an estimated $41.5K sold.
Based on aggregated 13F filings for Q4 2024.